During the corresponding time, Avinger Inc recorded a revenue increase by 2.74 % year on year, sequentially revenue grew by 3.48 %. While revenue at the Avinger Inc 's corporate clients
Avinger Inc's Comment on Sales, Marketing and Customers
The company primarily serves hospitals, which purchase its products designed for the treatment of peripheral artery disease (PAD). Its product portfolio includes Pantheris atherectomy devices and Lightbox imaging consoles, all intended to address clinical needs in vascular disease treatment. Revenues are generated from sales of PAD catheters, Lightbox imaging consoles, and related services in the United States and select international markets. Pantheris devices qualify for existing reimbursement codes applicable to other atherectomy products, facilitating hospital adoption. The company is developing future products compatible with its Lumivascular platform to enhance hospital value. Revenue was affected by the COVID-19 pandemic due to deferred elective procedures, staffing shortages, resource constraints among customers, and competition for commercial team talent. The product lineup includes FDA-cleared and CE-marked devices such as Lightbox, Lightbox 3, Pantheris SV, Pantheris (Next-Generation), Ocelot series, Tigereye series, and Pantheris LV, all intended for vascular disease treatment and hospital use.
Avinger Inc’s Comment on Sales, Marketing and Customers
The company primarily serves hospitals, which purchase its products designed for the treatment of peripheral artery disease (PAD). Its product portfolio includes Pantheris atherectomy devices and Lightbox imaging consoles, all intended to address clinical needs in vascular disease treatment. Revenues are generated from sales of PAD catheters, Lightbox imaging consoles, and related services in the United States and select international markets. Pantheris devices qualify for existing reimbursement codes applicable to other atherectomy products, facilitating hospital adoption. The company is developing future products compatible with its Lumivascular platform to enhance hospital value. Revenue was affected by the COVID-19 pandemic due to deferred elective procedures, staffing shortages, resource constraints among customers, and competition for commercial team talent. The product lineup includes FDA-cleared and CE-marked devices such as Lightbox, Lightbox 3, Pantheris SV, Pantheris (Next-Generation), Ocelot series, Tigereye series, and Pantheris LV, all intended for vascular disease treatment and hospital use.
Sources:
Avinger Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Avinger Inc’s corporate clients.
For your research, we’ve provided 9 tables on Avinger Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
